title: [Association of immunomodulators and HLA antigens in rheumatoid arthritis].
abstract: We studied the association between HLA antigens and clinical response to immunomodulators or the toxic effects of immunomodulators in 191 patients with rheumatoid arthritis (RA). All patients received nonsteroidal anti-inflammatory drugs. Fifty-seven patients were treated with auranofin, 61 patients with penicillamine and 45 patients with lobenzarit. We found that HLA-Cw 1 is significantly (p less than 0.05) associated with a substantial clinical response to auranofin in RA patients (65% vs 33% of Cw 1-negative patients). We observed that HLA-DR 4 is a risk factor for the occurrence of toxic reactions to penicillamine (45% vs 21% of DR 4-negative patients: p less than 0.05) and that HLA-DRw 9 is a risk factor in the case of lobenzarit (62% vs 32% of DRw 9-negative patients: p less than 0.05). HLA-A 24-positive patients with RA experienced a low frequency of side effects from auranofin (16% vs 37% of A 24-negative patients: p less than 0.05). HLA-A 2 or Cw 7-positive patients with RA experienced a low frequency of side effects from penicillamine (12% vs 49% of A 2-negative patients: p less than 0.01, 17% vs 46% of Cw 7-negative patients: p less than 0.05). Our data demonstrated that HLA antigens are significantly associated with a clinical response to immunomodulators and the toxic effects of immunomodulators in patients with RA.
authors.forename: K
authors.initials: K
authors.lastname: Taneichi
authors.forename: I
authors.initials: I
authors.lastname: Watanabe
authors.forename: I
authors.initials: I
authors.lastname: Sakai
authors.forename: H
authors.initials: H
authors.lastname: Shibaki
mesh_terms: D000276:Adjuvants, Immunologic / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D001310:Auranofin / Q000627:therapeutic use; D005260:Female; D006680:HLA Antigens / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010396:Penicillamine / Q000627:therapeutic use; D062367:ortho-Aminobenzoates / Q000627:therapeutic use
chemical_list: D000276:Adjuvants, Immunologic; D006680:HLA Antigens; D062367:ortho-Aminobenzoates; D001310:Auranofin; C015735:lobenzarit; D010396:Penicillamine